

Edgar Filing: EXELIXIS INC - Form 10-Q/A

EXELIXIS INC  
Form 10-Q/A  
September 17, 2001

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

AMENDMENT NO.1 TO  
FORM 10-Q

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: JUNE 30, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 0-30235

EXELIXIS, INC.

(Exact name of registrant as specified in its charter)

Delaware	04-3257395
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

170 Harbor Way  
P.O. Box 511  
South San Francisco, CA 94083  
(Address of principal executive offices, including zip code)  
(650) 837-7000  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes  No

As of July 31, 2001, there were 49,161,649 shares of the registrant's common stock outstanding.

# Edgar Filing: EXELIXIS INC - Form 10-Q/A

## EXPLANATORY NOTE

Exelixis, Inc. is filing this Amendment No. 1 to Form 10-Q as an exhibit-only filing. Exelixis is refiling Exhibit 10.28, Collaboration Agreement, dated May 22, 2001, by and between Exelixis, Inc. and Protein Design Labs, Inc., and confidential treatment has been requested for certain portions of such exhibit.

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amendment to report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 17, 2001

EXELIXIS, INC.

/s/ Glen Y. Sato

-----  
Glen Y. Sato  
Chief Financial Officer, Vice President of  
Legal Affairs and Secretary  
(Principal Financial and Accounting Officer)

## INDEX TO EXHIBITS

Exhibit Number	Description of Document
-----	-----
2.1	Share Exchange and Assignment Agreement, dated April 23, 2001, by and among Exelixis, Inc. and the Artemis stockholders named therein. (1)
3.1	Amended and Restated Certificate of Incorporation (2)
3.2	Amended and Restated Bylaws (2)
4.1	Specimen Common Stock Certificate (2)
4.2*	Form of Convertible Promissory Note, dated May 22, by and between Exelixis, Inc. and Protein Design Labs, Inc.
4.3*	Form of Note Purchase Agreement, dated May 22, by and between Exelixis, Inc. and Protein Design Labs, Inc.
10.28**	Collaboration Agreement, dated May 22, 2001, by and between Exelixis, Inc. and Protein Design Labs, Inc.
-----	
(1)	Filed with Exelixis' Item 2 Current Report on Form 8-K filed on May 15, 2001 and incorporated herein by reference.
(2)	Filed with Exelixis' Registration Statement on Form S-1, as amended (No.

Edgar Filing: EXELIXIS INC - Form 10-Q/A

333-96335), declared effective by the Securities and Exchange Commission on April 10, 2000, and incorporated herein by reference.

\* Previously filed.

\*\* Filed herewith, and confidential treatment requested for certain portions of this exhibit.